Ablynx

Founded in 2018, Ablynx, a Sanofi company is engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. The company is headquartered in Ghent/Zwijnaarde, Belgium.